Therapeutic Advances in Adult B-cell Acute Lymphoblastic Leukemia with KMT2A Rearrangements Authors: Shen-Hao Liu, Ai-Ni Deng, Hui-Ying Li, Kai-Wen Tan, Sheng-Li Xue, Hai-Ping Dai Published: 2026 ABSTRACT B-cell acute lymphoblastic leukemia (ALL) with KMT2A rearrangements (KMT2Ar B-ALL) represents a distinct, high-risk subtype in adults, characterized by aggressive disease biology, high relapse rates, and inferior long-term survival. Conventional intensive chemotherapy, even when consolidated with allogeneic hematopoietic stem cell transplantation (allo-HSCT), yields suboptimal outcomes, underscoring the need for novel therapeutic approaches. In recent years, substantial progress has been made with the introduction of antibody-based immunotherapies, cellular immunotherapies, and small molecular inhibitors, reshaping the treatment landscape for this challenging subgroup. This review provides a comprehensive overview of current and emerging therapeutic strategies for adult patients with KMT2Ar B-ALL. We summarize outcomes associated with pediatric-inspired chemotherapy and allo-HSCT, focus on clinical evidence for antibody-based immunotherapy including blinatumomab and inotuzumab ozogamicin, across frontline, consolidation, and relapsed or refractory settings. Advances in cellular immunotherapy, particularly CD19-directed chimeric antigen receptor T-cell therapy, are discussed, with a focus on unique resistance mechanisms such as antigen loss and lineage switch. In addition, we review the biological rationale, efficacy and emerging resistance mechanisms of menin inhibitors, a promising class of agents specifically targeting the epigenetic dependency of KMT2A-rearranged leukemia. Finally, other molecular approaches, including epigenetic modifiers, apoptosis pathway inhibitors, and signaling pathway inhibitors are discussed. Despite these advances, treatment resistance and disease relapse remain major obstacles. These ongoing challenges highlight the urgent need for multi-center, prospective trials to investigate rational combination strategies to improve outcomes for adults with KMT2Ar B-ALL. Introduction B-cell acute lymphoblastic leukemia (B-ALL) is a hematologic malignancy characterized by blocked differentiation and uncontrolled proliferation of malignant B-lymphoid progenitors [1]. Patients with B-ALL account for approximately 25–30% of all adult acute leukemia cases. Based on recurrent genetic abnormalities, B-ALL can be classified into more than 20 distinct molecular subtypes [2], each associated with characteristic clinical features and outcomes. The KMT2A (lysine [K]-methyltransferase 2 A) gene, located on chromosome 11q23.3, is frequently involved in chromosomal translocations, with more than 135 fusion partner genes reported to date [3]. KMT2A rearrangements (KMT2Ar) are detected in approximately 5–10% of adult patients with B-ALL and regarded as adverse prognostic indicators. Patients with KMT2Ar B-ALL exhibit high relapse rates and a strong predisposition to central nervous system involvement [4]. Reported 5-year relapse-free survival (RFS) and overall survival (OS) rates are approximately 18% and 25%, respectively [5]. With the curative strategy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), the 5-year OS rate increases to 47−67% [6, 7], which remains inferior compared to other molecular subtypes of adult B-ALL. The therapeutic landscape for KMT2Ar B-ALL is undergoing rapid evolution with the advent of immunotherapies and molecularly targeted agents (Fig. 1). In an effort to optimize treatment strategies and further improve clinical outcomes for patients with KMT2Ar B-ALL, we herein systematically review evidence from both retrospective and prospective clinical trials addressing recent therapeutic advances in this high-risk leukemia subtype. Fig. 1Therapeutic landscape in KMT2A-rearranged B-cell acute lymphoblastic leukemia. This schematic illustrates the cellular and molecular targets of current and emerging therapies. (Created with BioRender.com.) Therapeutic landscape in KMT2A-rearranged B-cell acute lymphoblastic leukemia. This schematic illustrates the cellular and molecular targets of current and emerging therapies. (Created with BioRender.com.) Chemotherapy and allogeneic stem cell transplantation A retrospective analysis from the GRAALL group included 141 adult patients with KMT2Ar B-ALL, with a median age of 42 years [8]. TP53 mutations, IKZF1 deletions, and persistent minimal residual disease (MRD) were identified as adverse prognostic factors. Patients treated with pediatric-inspired chemotherapy achieved significantly superior outcomes compared with those receiving conventional adult regimens, with 5-year OS and disease-free survival (DFS) rates of 53.3% and 50.3%, respectively [6, 7, 9, 10]. The proportion of patients undergoing allo-HSCT in first complete remission (CR1) in this study was comparable to that in other contemporary studies, suggesting that the benefit of survival was largely attributable to pediatric-inspired regimens. A retrospective study from the MD Anderson Cancer Center (MDACC) analyzed 50 adult patients with KMT2Ar ALL treated between 1984 and 2019 using hyper-CVAD-based chemotherapy [6]. Although the CR rate was high (88%), long-term outcomes remained poor, with the 5-year OS of only 18%. Survival did not significantly differ according to KMT2A fusion partners, and persistence of MRD was strongly associated with inferior OS and RFS. Among patients who underwent allo-HSCT in CR, the 5-year OS and RFS rates were 32% and 22%, respectively, improving to 47% and 39% among those treated after 2010, suggesting incremental benefits from advances in transplantation strategies and supportive care. The ECOG 2993 trial enrolled 85 adult B-ALL patients with t(4;11) [7]. The CR rate was 93%, with a 5-year OS of 35% and relapse rate of 45%. Survival was significantly superior in patients who received allo-HSCT compared with those who did not. Among the 31 patients who underwent allo-HSCT in CR1, 5-year OS was 56% and 67% for those receiving transplants from matched sibling donors and matched unrelated donors, respectively. Consistent findings were reported in a large retrospective analysis from the European Society for Blood and Marrow Transplantation [11], which included 151 patients with t(4;11) B-ALL undergoing allo-HSCT in CR1. The 2-year OS and leukemia-free survival (LFS) rates were 60% and 51%, respectively. The cumulative incidences of post-transplant relapse and non-relapse mortality (NRM) were 30% and 20%, respectively. Notably, these outcomes were comparable to those observed in patients with normal-karyotype B-ALL, supporting the role of allo-HSCT in mitigating the adverse prognosis associated with KMT2A rearrangements. B-cell directed immunotherapies B-ALL with KMT2A rearrangements exhibits a distinctive immunophenotype characterized by consistent expression of CD19, CD79a, and CD22, frequent co-expression of myeloid markers such as CD15, CD33, and CD68, and absence or weak expression of CD10 and terminal deoxynucleotidyl transferase (TdT) [4, 12, 13]. These features provide a strong biological rationale for B-cell directed immunotherapeutic strategies, which have been incorporated across multiple scenarios, including induction, MRD eradication, and salvage therapy for relapsed or refractory (R/R) disease [14]. Blinatumomab Blinatumomab is a bispecific T-cell engager targeting CD3 and CD19. The TOWER trial [15] compared blinatumomab with standard-of-care chemotherapy in 405 patients with R/R Philadelphia chromosome-negative B-ALL. For the overall cohort, blinatumomab demonstrated superior efficacy, achieving a significantly higher rate of CR with full, partial, or incomplete hematologic recovery compared with chemotherapy (44% vs. 25%, P < 0.001). Treatment with blinatumomab also resulted in a superior rate of event-free survival (EFS) of 31% and a median OS of 7.7 months in the blinatumomab group compared with the chemotherapy group. In this study, among the 16 patients with KMT2Ar, 11 received blinatumomab and 5 received chemotherapy, the outcome of these patients was not separately reported. Because of the small sample size, the results of Tower study should be interpreted with caution when applied to the KMT2Ar subgroup. In a phase 2 study from MDACC, blinatumomab was combined with intensive hyper-CVAD chemotherapy as frontline therapy for newly diagnosed B-ALL [16]. All patients achieved CR, and 97% of the overall cohort attained MRD negativity. Three patients with KMT2Ar were included, and one failed to achieve MRD negativity and experienced early relapse prior to blinatumomab use. Because of the limited sample size, the benefit of blinatumomab in the frontline setting for KMT2Ar B-ALL needs to be further investigated in larger cohorts. The role of blinatumomab in consolidation and maintenance therapy has also been explored. The phase 3 ECOG-ACRIN E1910 trial [17] demonstrated a survival benefit with blinatumomab consolidation in Ph-negative B-ALL who have achieved MRD-negativity. In this study, a total of 19 B-ALL patients with KMT2Ar were randomized, with 11 assigned to the blinatumomab arm and 8 to the chemotherapy-only arm. In a post-hoc analysis of this study, a potential benefit of blinatumomab in patients with high-risk genetic subtypes including KMT2Ar was observed [18]. Similarly, the GRAALL-2014-QUEST study [19], which incorporated blinatumomab into consolidation and maintenance for high-risk B-ALL, included 16 patients with KMT2Ar. In the overall high-risk cohort, increased rate of deep molecular remission (56% vs. 14%; P < 0.001), reduced relapse rate (20% vs. 41%; P = 0.009), and improved DFS (72% vs. 54%; P = 0.03) were also observed in patients treated with blinatumomab compared with those who did not. For the KMT2Ar subgroup, specific outcome data were not separately reported. Of note, these promising results were mostly based on limited sample size or indirect analyses on the KMT2Ar subgroup. A phase 2 study from China evaluated reduced-intensity chemotherapy followed by 2–4 weeks of blinatumomab as frontline induction therapy for Ph-negative B-ALL [20]. Among 35 enrolled patients, three had KMT2A rearrangements. All patients achieved remission following induction, with 1-year OS and progression-free survival (PFS) rates of 97.1% and 82.2% in the overall cohort, respectively. This study confirmed the feasibility of blinatumomab-containing induction treatment for KMT2Ar B-ALL, though the long-term benefit of blinatumomab in this subtype needs to be investigated in more patients. In an international multicenter phase 2 study (EudraCT number: 2016–004674−17), 30 infants with KMT2Ar B-ALL received blinatumomab in combination with chemotherapy [21] and achieved 4-year OS and DFS of 93.3% and 83.3%, respectively [22]. These inspiring results suggest that a clinical trial of blinatumomab specifically designed for adult patients with KMT2Ar B-ALL is warranted. Despite these encouraging outcomes, relapse after blinatumomab has been reported in KMT2Ar B-ALL [23, 24]. Lineage switch from B-ALL to acute myeloid leukemia (AML), particularly in cases with t(4;11)/KMT2A::AFF1, represents a recognized resistance mechanism. Proposed explanations include clonal relatedness between B-ALL and AML populations, immunologic selection pressure leading to CD19-negative escape, epigenetic reprogramming, and intrinsic bilineage potential of the leukemic clone [25]. These observations underscore the need for combination strategies and alternative antigen-directed therapies in this high-risk subgroup. Inotuzumab ozogamicin Inotuzumab ozogamicin (InO), an antibody-drug conjugate targeting CD22, is approved for R/R B-ALL. In the INO-VATE study [26], InO achieved significantly higher remission rates than standard chemotherapy (80.7% vs. 29.4%; P < 0.001). In a post-hoc genetic subgroup analysis [27], eight patients with KMT2Ar B-ALL were identified. Two patients with KMT2Ar B-ALL received InO. Both achieved remission, but exhibited marked downregulation of CD22 (< 10%) after treatment with InO, with a short PFS of only 1.7 months. In a post-hoc analysis of the INO-VATE study, patients with KMT2Ar showed lower baseline CD22 expression levels compared with those without KMT2A abnormalities [28]. In another study, median CD22 site density was significantly lower in KMT2Ar R/R B-ALL patients than in those without KMT2Ar [29]. Although low-level CD22 expression may still support the internalization and cytotoxicity of InO in preclinical studies [30], lower CD22 site density may limit the amount of calicheamicin delivered per leukemic cell, which would impair the depth and duration of response to InO. Collectively, these data suggest that B-ALL patients with KMT2Ar might show a suboptimal response to InO monotherapy due to the unique expression of CD22. Several studies have explored intensified or frontline immunotherapy incorporating InO. A pilot study combined blinatumomab and/or InO with intensive chemotherapy in newly diagnosed Ph-negative B-ALL [16, 31, 32]. Eight patients with KMT2Ar B-ALL were included. Among patients with high-risk cytogenetics, including KMT2Ar, all achieved CR or CR with incomplete hematologic recovery (CR/CRi), with 55% attaining MRD negativity. The 3-year OS rate reached 89%, supporting the feasibility of dual immunotherapeutic approaches in high-risk B-ALL including KMT2Ar. In contrast, the EWALL-INO study [33] evaluated InO combined with low-intensity chemotherapy as frontline therapy for older patients. For the overall cohort, the 1-year relapse rate was 77.8%. The 1-year OS and RFS were 27.2% and 22.2%, respectively, declining to 9% and 11.1% at 2 years. This study enrolled 11 patients with KMT2Ar B-ALL. Response rates and survival of patients with KMT2Ar were not reported separately. To be noted, the unfavorable outcomes of this study weakened the application of InO with reduced-intensity chemotherapy for older patients with R/R B-ALL. A chemotherapy-free regimen combining InO and blinatumomab was evaluated in elderly patients with Ph-negative B-ALL [34]. Although 46% of patients harbored high-risk cytogenetic abnormalities, only two had KMT2Ar. Overall outcomes were favorable, with an overall response rate (ORR) of 93%, 1-year OS of 73%, and 1-year PFS of 64%. Two patients suffered relapse, one harbored KMT2Ar. Because of limited number of patients included, whether combined immunotherapy strategy would improve the outcome in KMT2Ar patients remains to be investigated. Cellular immunotherapy Cellular immunotherapy, particularly chimeric antigen receptor (CAR) T-cell therapy, has revolutionized the treatment landscape of B-ALL. The phase 2 ZUMA-3 trial assessed brexucabtagene autoleucel in adult patients with R/R B-ALL [35, 36], reporting a CR or CRi rate of 63%. Median OS and RFS were 25.6 months and 11.6 months, respectively. Treatment response and outcome of patients with KMT2Ar were not disclosed separately in this study. In a retrospective study evaluating the efficacy of brexucabtagene autoleucel in R/R Ph-negative B-ALL, patients with KMT2Ar had the lowest CR/CRi rate (71%), the highest rate of progressive disease (29%), and markedly shorter median EFS (4.1 months) and median OS (6.8 months) compared with other high-risk subtypes [37]. KMT2Ar was found to be independently associated with inferior OS. Notably, patients with KMT2Ar experienced a higher incidence of myeloid transformation at relapse compared with other subgroups (21% vs. 0–2%, respectively). In the FELIX trial, obecabtagene autoleucel demonstrated comparable ORR in the overall population and in patients with high disease burden (78% vs. 77%) [38]. However, outcomes concerning B-ALL patients with KMT2Ar were also not independently reported in this study. Inaticabtagene autoleucel is the only approved anti-CD19 CAR-T product for R/R B-ALL in China at present. A real-world study evaluated inaticabtagene autoleucel in 48 heavily pretreated patients with R/R B-ALL and high-risk genetic features [39], the median RFS and duration of remission were 12.4 months and 20.7 months, respectively. Seven patients (14.6%) harbored KMT2A rearrangements; however, efficacy and safety outcomes for this subgroup were not analyzed separately. A retrospective analysis including pediatric and young adult patients treated with CD19-directed CAR-T therapy (tisagenlecleucel or huCART19) demonstrated comparable CR rates between patients with KMT2Ar B-ALL and the overall cohort (92% vs. 94%) [40]. Despite high initial response rates, the 2-year OS for patients with KMT2Ar B-ALL was significantly lower (59% vs. 70%). Notably, five of six patients with KMT2Ar experienced CD19-negative relapse accompanied by myeloid lineage transformation. Multivariate analysis identified KMT2A rearrangement as an independent adverse prognostic factor following CAR-T therapy. Similarly, a retrospective study from the Center for International Blood and Marrow Transplant Research analyzed 768 patients with R/R B-ALL treated with commercial tisagenlecleucel [41]. KMT2A rearrangement was independently associated with inferior RFS and OS. Five patients showed lineage switch to AML at relapse. Consistent findings were reported by Gardner et al., who observed myeloid lineage transformation in two of seven patients with KMT2Ar B-ALL relapsing after CD19 CAR-T therapy [42]. Given the high incidence of antigen-negative relapse or lineage switch, alternative cellular immunotherapy strategies targeting non-CD19 antigens are under investigation. Using unbiased surface proteomics, CD72 has been identified as a promising target in KMT2Ar B-ALL, and CD72-directed CAR-T cells have demonstrated potent cytotoxicity in vitro and in murine models [43]. Additionally, a preclinical study showed that universal dual-targeted CD19/CD133 CAR-invariant natural killer T (CAR-iNKT) cells effectively eradicated intramedullary and leptomeningeal KMT2Ar leukemia, with efficacy comparable to CD19-directed CAR-T cells [44]. Menin inhibitors KMT2A is a key epigenetic regulator that interacts with menin, a protein encoded by the MEN1 gene [45]. Through its SET domain, KMT2A catalyzes histone H3 lysine 4 (H3K4) methylation at target gene promoters, thereby regulating transcription, cell cycle progression, and genomic stability [46–49]. In KMT2Ar leukemia, fusion proteins aberrantly enhance transcriptional elongation and constitutively activate gene programs associated with impaired differentiation and apoptosis resistance [50–52], leading to overexpression of downstream targets such as HOXA cluster genes and MEIS1, which disrupt normal hematopoietic differentiation [53, 54]. Menin inhibitors disrupt the interaction between menin and KMT2A fusion proteins, thereby releasing the differentiation blockade and inducing apoptosis in KMT2Ar leukemia cells [55–57]. Revumenib is the first menin inhibitor approved by the U.S. Food and Drug Administration for the treatment of R/R acute leukemia with KMT2A rearrangements [58]. In addition, several other menin inhibitors, including ziftomenib, bleximenib, enzomenib, DS-1594, BN104, icovamenib, and HMPL-506, have also demonstrated promising efficacy and tolerability in early-phase clinical trials [59, 60]. In the phase 1/2 AUGMENT-101 study evaluating the safety and efficacy of revumenib for R/R acute leukemia [61–63], 13 patients with KMT2Ar ALL were included. The ORR for these patients was 46% (95% CI, 19%−75%), with a CR + CRh rate of 23% (95% CI, 5−54%), and the median duration of response was not reached (95% CI, 0.9 months-not estimable). Treatment-related adverse events were observed in 80% of patients, and the incidence of differentiation syndrome was 13% [64]. The subsequent AUGMENT-102 study evaluated revumenib in combination with fludarabine and cytarabine in 27 patients, including 3 with ALL [65]. The ORR was 52%, with no reported cases of differentiation syndrome, although QTc prolongation occurred in four patients. These results suggest that combining revumenib with cytotoxic chemotherapy may offer a tolerable and effective strategy for ALL patients with KMT2Ar. Early-phase trials of other menin inhibitors are ongoing. The ITCC-101/APAL2020K phase 1 study evaluated ziftomenib in combination with fludarabine and cytarabine in pediatric patients with R/R acute leukemia [66]. Another phase 1 trial of bleximenib monotherapy also enrolled patients with B-ALL [67]. However, outcome data from these studies have not yet been reported. In another study, enzomenib was administered to two patients with KMT2Ar ALL, resulting in downregulation of stemness-associated genes (HOXA9, MEIS1, PBX3) and increased expression of the myeloid differentiation marker CD11b, providing mechanistic evidence of differentiation induction [68]. More recently, preliminary clinical data on enzomenib were presented at the 2025 ASH Annual Meeting [69]. Among 116 patients with R/R KMT2Ar acute leukemia, the majority had AML (93.1%), and the number of ALL patients was not explicitly reported; thus, the efficacy of enzomenib specifically in KMT2Ar ALL remains to be established. Resistance to menin inhibitors has emerged as a clinical challenge. Acquired somatic mutations in MEN1 that impair drug binding have been identified as a common mechanism of resistance, with cross-resistance observed among different menin inhibitors [70]. Notably, preclinical data suggest that bleximenib retains activity against KMT2Ar ALL cell lines harboring MEN1 mutations and exhibits synergistic effects when combined with BCL-2 inhibitors [71]. Furthermore, MEN1 mutations are not universally detected at relapse, indicating additional resistance mechanisms. Epigenetic plasticity has been proposed as an alternative pathway, whereby sustained suppression of HOXA/MEIS1 expression requires establishment of a repressive chromatin state mediated by non-canonical polycomb repressive complex 1.1 (PRC1.1). Functional loss of PRC1.1 may therefore contribute to resistance to menin inhibition [72, 73]. Other small molecular inhibitors Epigenetic drugs DNA methyltransferase (DNMT) inhibitors, including azacitidine and decitabine, exert antileukemic effects by inhibiting DNA methylation and reactivating silenced tumor suppressor genes. Decitabine has been shown to induce cell cycle arrest and promote apoptosis in KMT2Ar B-ALL cell lines. In addition, decitabine demonstrated synergistic antileukemic activity when combined with conventional chemotherapy, resulting in enhanced suppression of cell proliferation in vitro [74]. However, clinical data supporting the efficacy of DNMT inhibitors in adult KMT2Ar B-ALL remain limited. Histone deacetylase (HDAC) inhibitors, such as vorinostat, romidepsin, and chidamide, inhibit histone deacetylation, leading to chromatin relaxation and altered gene transcription [75, 76]. Class I HDAC inhibitors, particularly selective HDAC1/2 inhibitors, have shown antileukemic activity against KMT2Ar B-ALL in both in vitro and in vivo models [77, 78]. In addition, knockdown of class II HDAC isoforms, including HDAC4 and HDAC5, induces apoptosis and cell cycle arrest in KMT2Ar ALL cells in vitro. LMK-235, a selective HDAC4/5 inhibitor, suppressed proliferation of KMT2Ar ALL cell lines and primary cells and demonstrated synergistic effects with BCL-2 inhibitors in vitro [79]. However, LMK-235 failed to exhibit antileukemic efficacy in murine models. Collectively, these findings suggest that HDAC inhibitors have limited activity as monotherapy in vivo and may require combination strategies to achieve meaningful clinical benefit in KMT2Ar ALL. DOT1L inhibitors Disruptor of telomeric silencing 1-like (DOT1L) is a histone methyltransferase responsible for methylation of histone H3 lysine 79 (H3K79) and plays a critical role in regulating leukemia-associated gene expression. KMT2A fusion proteins aberrantly recruit DOT1L to form oncogenic transcriptional complexes. Pharmacologic inhibition of DOT1L reverses these epigenetic alterations, reduces expression of HOXA and MEIS1, promotes cellular differentiation, and suppresses leukemic proliferation [80]. Pinometostat, a selective DOT1L inhibitor, demonstrated antileukemic activity in preclinical KMT2Ar models; however, its clinical efficacy as monotherapy has been limited. In a phase 1 trial enrolling adult and pediatric patients with KMT2Ar leukemia, pinometostat monotherapy resulted in a modest response rate of only 3.9% [81]. More recently, preclinical studies have shown synergistic antileukemic effects when pinometostat was combined with the menin inhibitor revumenib in KMT2Ar ALL models, suggesting that dual targeting of menin and DOT1L may represent a promising therapeutic strategy [72]. Targeting the apoptotic pathway Members of the B-cell lymphoma 2 (BCL-2) protein family regulate the intrinsic mitochondrial apoptotic pathway through complex interactions between pro-apoptotic and anti-apoptotic proteins [82]. BCL-2 inhibition has demonstrated substantial clinical activity in AML and is under investigation in T-ALL [83, 84]. Transcriptomic analyses have shown significantly higher BCL-2 expression in patients with KMT2Ar ALL compared with other ALL subtypes [85]. In addition, overexpression of BCL-2 has been detected in primary leukemic cells from patients with t(4;11), potentially mediated by DOT1L-dependent enrichment of H3K79me2/3 at the BCL2 locus. Consistent with this biological dependency, cell lines with t(4;11) exhibit marked sensitivity to the selective BCL-2 inhibitor venetoclax (ABT-199) in vitro [86]. Clinically, venetoclax combined with mini-hyper-CVD chemotherapy was evaluated in a prospective study of 22 patients with R/R ALL [87]. The overall CR/CRi rate was 57%, with a median duration of response of 6.3 months. Median OS was 7.1 months, and the 1-year OS rate was 29%. Only one patient with t(4;11)-positive ALL was included, and subgroup-specific efficacy data were not reported, precluding firm conclusions regarding the role of venetoclax in KMT2Ar ALL. RAS-RTK signaling pathway inhibitors Mutations affecting the RAS pathway are common in KMT2Ar ALL. In the GRAALL studies, activating mutations in NRAS and KRAS were detected in approximately 20% and 19% of patients, respectively. These alterations are often subclonal and primarily affect the receptor tyrosine kinase-RAS signaling cascade, frequently co-occurring with abnormalities in tumor suppressor genes such as TP53, CDKN2A, and IKZF1 [8]. Mitogen-activated protein kinase kinase (MEK) is a central component of the MAPK signaling pathway. MEK inhibitors, including trametinib and selumetinib, have demonstrated antileukemic activity in KMT2Ar ALL cell lines harboring RAS mutations. Notably, MEK inhibition has also enhanced sensitivity to glucocorticoids in both RAS-mutated and RAS-wild-type ALL cells [88]. Despite these encouraging preclinical findings, clinical data supporting MEK inhibitors in KMT2Ar ALL remain scarce. FLT3 inhibitors FLT3 mutations are also detected in a subset of patients with KMT2Ar ALL [8]. Preclinical studies have demonstrated sequence-dependent synergistic effects between FLT3 inhibitors and chemotherapy [89, 90]. However, clinical trials have not shown a clear therapeutic benefit. In the Children’s Oncology Group AALL0631 trial, the addition of the first-generation FLT3 inhibitor lestaurtinib following induction therapy failed to improve EFS in infants with KMT2Ar ALL [91]. Similarly, a small study evaluating the second-generation FLT3 inhibitor quizartinib in 4 patients (3 infants and 1 adolescent) with KMT2Ar ALL did not demonstrate objective clinical responses [92]. These findings suggest that FLT3 inhibition alone might be insufficient to overcome the aggressive biology of KMT2Ar ALL. A summary of key clinical studies in KMT2A-rearranged B-ALL is presented in Tables 1 and 2, encompassing chemotherapy, immunotherapy, and targeted therapy regimens. Table 1Summary of Key Retrospective Studies in KMT2A-Rearranged B-cell Acute Lymphoblastic LeukemiaTherapeutic CategoryIntervention & Study DetailsPatients (n)KMT2Ar Cohort (n)Key Efficacy OutcomesSurvival Outcomesconventional chemotherapy & HSCT• GRAALL study [8]• intensive pediatric-inspired chemotherapy ± HSCTde novo Ph- adult BCP-ALL (n = 1091)KMT2Ar ALL (n = 141)t(4;11):86% (n = 121)t(11;19):8.5% (n = 12)other type:5.7% (n = 8)• KMT2Ar ALL:CR: 92.9%• KMT2Ar ALL:5-year OS/DFS/CIR: 53.3%/50.3%/40.7%• MD Anderson Cancer Center study [6]• intensive chemotherapy (e.g., Hyper-CVAD) ± HSCTde novo adult ALL (n = 1102)KMT2Ar ALL (n = 50)t(4;11): 82% (n = 42)t(11;19): 8% (n = 4)t(9;11): 2% (n = 1)other type: 6% (n = 3)CR in KMT2Ar ALL: 88%5-year OS/RFS in KMT2Ar ALL: 18%/15%5-year OS/RFS in HSCT Group: 32%/22%5-year OS/RFS in HSCT Group (post-2010): 47%/39%• EBMT study [11]• HSCT in CR1t(4;11)-positive B-ALL in CR1 (n = 115)all enrollednot available2-year OS/LFS: 60%/51%relapse rate: 30%immunotherapy• Leonard et al. (ASH 2025) [37]• Brexucabtagene autoleucel (CD19 CAR-T)adult R/R Ph-negative B-ALL (n = 286)KMT2Ar B-ALL (n = 16)• KMT2Ar ALL:CR/CRi: 71%; Progressive disease: 29%• Total high-risk B-ALL:CR/CRi:90.5%• KMT2Ar ALL:Median EFS: 4.1 monthsmedian OS: 6.8 monthsmyeloid transformation at relapse: 21%• Leahy et al. (pooled analysis) [40]• Tisagenlecleucel/huCART19 (CD19 CAR-T)pediatric/young adult R/R B-ALL (n = 231)KMT2Ar B-ALL (n = 25)• KMT2Ar ALL:CR: 92%• Total R/R B-ALL:CR: 94%• KMT2Ar ALL:2-year OS: 59%2-year RFS: 46%• total R/R B-ALL:2-year OS:70% (high risk) vs. 66–79% (other group)2-year RFS: 63% (high risk) vs. 55–63% (other group)• John et al. (CIBMTR) [41]• Tisagenlecleucel (CD19 CAR-T)pediatric/young adult R/R B-ALL (n = 768)KMT2Ar B-ALL (n = 110)• KMT2Ar ALL:Best response of CR/CRi: 74.7%• Total R/R B-ALL:Best response of CR/CRi: 86%• KMT2Ar ALL:1-year OS: 56.3%1-year RFS: 52.6%• total R/R B-ALL:1-year OS: 79.4%1-year RFS: 61.8%AL acute leukemia, ALL acute lymphoblastic leukemia, B-ALL B-cell ALL, BCP-ALL, B-cell precursor acute lymphoblastic leukemia, CAR-T chimeric antigen receptor T-cell, CIBMTR Center for International Blood and Marrow Transplant Research, CIR cumulative incidence of relapse, CR complete remission, CRi CR with incomplete hematologic recovery, CR1 first complete remission, DFS disease-free survival, EBMT European Society for Blood and Marrow Transplantation, HSCT hematopoietic stem cell transplantation, KMT2Ar KMT2A-rearranged,LFS leukemia-free survival, OS overall survival, Ph- Philadelphia chromosome-negative,Pts Patients, R/R relapsed/refractory, RFS relapse-free survival Table 1Summary of Key Retrospective Studies in KMT2A-Rearranged B-cell Acute Lymphoblastic LeukemiaTherapeutic CategoryIntervention & Study DetailsPatients (n)KMT2Ar Cohort (n)Key Efficacy OutcomesSurvival Outcomesconventional chemotherapy & HSCT• GRAALL study [8]• intensive pediatric-inspired chemotherapy ± HSCTde novo Ph- adult BCP-ALL (n = 1091)KMT2Ar ALL (n = 141)t(4;11):86% (n = 121)t(11;19):8.5% (n = 12)other type:5.7% (n = 8)• KMT2Ar ALL:CR: 92.9%• KMT2Ar ALL:5-year OS/DFS/CIR: 53.3%/50.3%/40.7%• MD Anderson Cancer Center study [6]• intensive chemotherapy (e.g., Hyper-CVAD) ± HSCTde novo adult ALL (n = 1102)KMT2Ar ALL (n = 50)t(4;11): 82% (n = 42)t(11;19): 8% (n = 4)t(9;11): 2% (n = 1)other type: 6% (n = 3)CR in KMT2Ar ALL: 88%5-year OS/RFS in KMT2Ar ALL: 18%/15%5-year OS/RFS in HSCT Group: 32%/22%5-year OS/RFS in HSCT Group (post-2010): 47%/39%• EBMT study [11]• HSCT in CR1t(4;11)-positive B-ALL in CR1 (n = 115)all enrollednot available2-year OS/LFS: 60%/51%relapse rate: 30%immunotherapy• Leonard et al. (ASH 2025) [37]• Brexucabtagene autoleucel (CD19 CAR-T)adult R/R Ph-negative B-ALL (n = 286)KMT2Ar B-ALL (n = 16)• KMT2Ar ALL:CR/CRi: 71%; Progressive disease: 29%• Total high-risk B-ALL:CR/CRi:90.5%• KMT2Ar ALL:Median EFS: 4.1 monthsmedian OS: 6.8 monthsmyeloid transformation at relapse: 21%• Leahy et al. (pooled analysis) [40]• Tisagenlecleucel/huCART19 (CD19 CAR-T)pediatric/young adult R/R B-ALL (n = 231)KMT2Ar B-ALL (n = 25)• KMT2Ar ALL:CR: 92%• Total R/R B-ALL:CR: 94%• KMT2Ar ALL:2-year OS: 59%2-year RFS: 46%• total R/R B-ALL:2-year OS:70% (high risk) vs. 66–79% (other group)2-year RFS: 63% (high risk) vs. 55–63% (other group)• John et al. (CIBMTR) [41]• Tisagenlecleucel (CD19 CAR-T)pediatric/young adult R/R B-ALL (n = 768)KMT2Ar B-ALL (n = 110)• KMT2Ar ALL:Best response of CR/CRi: 74.7%• Total R/R B-ALL:Best response of CR/CRi: 86%• KMT2Ar ALL:1-year OS: 56.3%1-year RFS: 52.6%• total R/R B-ALL:1-year OS: 79.4%1-year RFS: 61.8%AL acute leukemia, ALL acute lymphoblastic leukemia, B-ALL B-cell ALL, BCP-ALL, B-cell precursor acute lymphoblastic leukemia, CAR-T chimeric antigen receptor T-cell, CIBMTR Center for International Blood and Marrow Transplant Research, CIR cumulative incidence of relapse, CR complete remission, CRi CR with incomplete hematologic recovery, CR1 first complete remission, DFS disease-free survival, EBMT European Society for Blood and Marrow Transplantation, HSCT hematopoietic stem cell transplantation, KMT2Ar KMT2A-rearranged,LFS leukemia-free survival, OS overall survival, Ph- Philadelphia chromosome-negative,Pts Patients, R/R relapsed/refractory, RFS relapse-free survival Summary of Key Retrospective Studies in KMT2A-Rearranged B-cell Acute Lymphoblastic Leukemia • GRAALL study [8] • intensive pediatric-inspired chemotherapy ± HSCT KMT2Ar ALL (n = 141) t(4;11):86% (n = 121) t(11;19):8.5% (n = 12) other type:5.7% (n = 8) • KMT2Ar ALL: CR: 92.9% • KMT2Ar ALL: 5-year OS/DFS/CIR: 53.3%/50.3%/40.7% • MD Anderson Cancer Center study [6] • intensive chemotherapy (e.g., Hyper-CVAD) ± HSCT KMT2Ar ALL (n = 50) t(4;11): 82% (n = 42) t(11;19): 8% (n = 4) t(9;11): 2% (n = 1) other type: 6% (n = 3) 5-year OS/RFS in KMT2Ar ALL: 18%/15% 5-year OS/RFS in HSCT Group: 32%/22% 5-year OS/RFS in HSCT Group (post-2010): 47%/39% • EBMT study [11] • HSCT in CR1 2-year OS/LFS: 60%/51% relapse rate: 30% • Leonard et al. (ASH 2025) [37] • Brexucabtagene autoleucel (CD19 CAR-T) • KMT2Ar ALL: CR/CRi: 71%; Progressive disease: 29% • Total high-risk B-ALL: CR/CRi:90.5% • KMT2Ar ALL: Median EFS: 4.1 months median OS: 6.8 months myeloid transformation at relapse: 21% • Leahy et al. (pooled analysis) [40] • Tisagenlecleucel/huCART19 (CD19 CAR-T) • KMT2Ar ALL: CR: 92% • Total R/R B-ALL: CR: 94% • KMT2Ar ALL: 2-year OS: 59% 2-year RFS: 46% • total R/R B-ALL: 2-year OS:70% (high risk) vs. 66–79% (other group) 2-year RFS: 63% (high risk) vs. 55–63% (other group) • John et al. (CIBMTR) [41] • Tisagenlecleucel (CD19 CAR-T) • KMT2Ar ALL: Best response of CR/CRi: 74.7% • Total R/R B-ALL: Best response of CR/CRi: 86% • KMT2Ar ALL: 1-year OS: 56.3% 1-year RFS: 52.6% • total R/R B-ALL: 1-year OS: 79.4% 1-year RFS: 61.8% AL acute leukemia, ALL acute lymphoblastic leukemia, B-ALL B-cell ALL, BCP-ALL, B-cell precursor acute lymphoblastic leukemia, CAR-T chimeric antigen receptor T-cell, CIBMTR Center for International Blood and Marrow Transplant Research, CIR cumulative incidence of relapse, CR complete remission, CRi CR with incomplete hematologic recovery, CR1 first complete remission, DFS disease-free survival, EBMT European Society for Blood and Marrow Transplantation, HSCT hematopoietic stem cell transplantation, KMT2Ar KMT2A-rearranged,LFS leukemia-free survival, OS overall survival, Ph- Philadelphia chromosome-negative,Pts Patients, R/R relapsed/refractory, RFS relapse-free survival Table 2Summary of Key Clinical Studies in KMT2A-Rearranged B-cell Acute Lymphoblastic LeukemiaTherapeutic CategoryIntervention & Study DetailsPatients (n)KMT2Ar Cohort (n)OutcomesSelected Notable Adverse Events (Grade ≥ 3)conventional chemotherapy & HSCT• ECOG2993 (NCT00002514) [7]• intensive chemotherapy ± HSCT• phase 3de novo adult ALLt(4;11)-positive B-ALL (n = 85)CR1 in t(4;11) ALL: 93%5-year OS/EFS in t(4;11) ALL: 35%/34%Relapse rate in t(4;11) ALL: 45%5-year OS in CR1 HSCT(MSD/URD): 56%/67%not availableimmunotherapy• MD Anderson Cancer Center study (NCT02877303) [16]• hyper-CVAD + blinatumomab• Phase 2de novo Ph- B-ALL (n = 38)KMT2Ar B-ALL (n = 3)CR in all pts: 100%3-year OS in all pts: 81%3-year RFS in all pts: 73%3-year OS in high-risk pts: 76%3-year RFS in high-risk pts: 66%CRS (grade ≥ 3: 3%); neurological events (grade 3: 11%); no treatment‑related deaths; treatment discontinuation due to neurotoxicity (3%)• ECOG-ACRIN E1910 (NCT02003222) [17]• blinatumomab + chemotherapy vs. chemotherapy• phase 3MRD-negative Ph- B-ALL (n = 224)KMT2Ar B-ALL (n = 66)•n = 11 (blin group)•n = 8 (chemo group)3-year OS: 85% (blin + chemo) vs. 68% (chemo)3-year RFS: 80% (blin + chemo) vs. 64% (chemo)neurologic or psychiatric adverse event (grade ≥ 3): 23% (blin + chemo) vs. 5% (chemo)• GRAALL-2014-QUEST (NCT03709719) [19]• blinatumomab vs. chemotherapy (consolidation/maintenance)• phase 2high-risk Ph- B-ALLKMT2Ar B-ALL (n = 16)2.5-year OS: 79% (blin) vs. 76% (chemo)2.5-year DFS: 72% (blin) vs. 54% (chemo)2.5-year CIR: 20% (blin) vs. 41% (chemo)not available• Lu et al. (NCT05557110) [20]• reduced-dose chemotherapy + blinatumomab induction• phase 2de novo Ph- B-ALL (n = 35)KMT2Ar B-ALL (n = 3)response rate after 2–4 weeks blin in all pts: 100%1-year OS in all pts: 97.1%1-year PFS in all pts: 82.2%CRS (grade ≥ 3: 9%); ICANS (any grade: 14%; all grade 1); no deaths within 4 weeks of induction• MD Anderson Cancer Center study (NCT02877303) [31, 32]• blinatumomab and/or inotuzumab ozogamicin-based intensive immunotherapy• phase 2de novo Ph- B-ALL (n = 71)high-risk cytogenetics Ph- B-ALL (n = 31)KMT2Ar B-ALL (n = 8)CR/CRi in high-risk group: 100%3-year OS: 89% (high-risk) vs. 82% (non-high-risk)3-year RFS: 74% (high-risk) vs. 80% (non-high-risk)no SOS or secondary myeloid neoplasm• EWALL-INO (NCT03249870) [33]• inotuzumab ozogamicin + low-intensity chemotherapy• phase 2elderly (≥ 55 years) Ph- B-ALL (n = 131)KMT2Ar B-ALL (n = 11)• KMT2Ar B-ALL:1-year OS/RFS/CIR: 27.2%/22.2%/77.8%2-year OS/RFS/CIR: 9%/11.1%/88.9%SOS: 1 case (grade 3) during induction 1• MD Anderson Cancer Center study [34]• inotuzumab ozogamicin + blinatumomab (chemo-free)• phase 2elderly (≥ 70 years or 60–70 years unfit) Ph- B-ALL (n = 14)KMT2Ar B-ALL (n = 2)ORR in all pts: 93%1-year CRD/OS/PFS in all pts: 70%/73%/64%ALT elevation: 1 case (grade 3); blinatumomab-related encephalopathy: 1 case (grade 3); no SOS or secondary myeloid neoplasms• Wang et al. (NCT04684147) [39]• Inaticabtagene Autoleucel (CD19 CAR-T)• real-worldadult R/R B-ALL (n = 67)KMT2Ar B-ALL (n = 7)• KMT2Ar B-ALL:CR/CRi: 85.7%MRD-neg: 100%• total R/R B-ALL:CR/CRi: 85.4%MRD-neg: 100%median OS: not reachedmedian RFS: 12.4 monthsmedian DOR: 20.7 monthsCRS:87.5%(grade ≥ 3:12.5%); ICANS:8.3%(grade ≥ 3:6.2%); HLH/MAS:6.2%(grade ≥ 3:2.1%)menin inhibitors• AUGMENT-101 (NCT04065399) [61–64]• revumenib (SNDX-5613) monotherapy• phase 1/2R/R AL(n = 68)KMT2Ar AL(n = 46)ORR:53%CR/CRh:30%CCyR in KMT2Ar AL:64%QTc prolongation (13%)R/R KMT2Ar AL(n = 97)KMT2Ar ALL (n = 13)• KMT2Ar ALL:ORR:46%CR/CRh:23%Median DOR: not reacheddifferentiation syndrome: ALL 13% vs. AML 28% vs. MPAL 33%; febrile neutropenia (13%); nausea (13%); no TRAE-related deaths• AUGMENT-102 (NCT05326516) [65]• revumenib (SNDX-5613) + chemotherapy (FA)• phase 1R/R KMT2Ar, NPM1m, NUP98r AL (n = 27)KMT2Ar AL (n = 24)ORR: 52%CR/CRi/CRp: 52%thrombocytopenia (63%); anemia (56%); febrile neutropenia (48%)• ITCC-101/APAL2020K (NCT06376162) [66]• ziftomenib (KO-539) + chemotherapy (FA)• phase 1R/R KMT2Ar, NPM1m, NUP98r pediatric ALrecruitingnot availablenot available• NCT04811560 [67]• bleximenib (JNJ-75276617) monotherapy• phase 1R/R KMT2Ar, NPM1m AL (n = 121)KMT2Ar AL (n = 73)ORR: 47%CR/CRh/CRi: 36%neutropenia (11%); thrombocytopenia (8%); differentiation syndrome (7%)• NCT04988555 [69]• enzomenib (DSP-5336) monotherapy• phase 1/2R/R AL (HOXA9/MEIS1 driven leukemia subsets) (n = 116)KMT2Ar AL (n = 61)• KMT2Ar AL (300 mg BID + CYP3A4 inhibitor):CR/CRh: 45.5%Median OS: 11.4 monthsdifferentiation syndrome (12.9%); no grade ≥ 3 QTc prolongationAL acute leukemia, ALL acute lymphoblastic leukemia, ALT alanine aminotransferase, B-ALL B-cell ALL,CAR-T chimeric antigen receptor T-cell, CCyR complete cytogenetic response, CIR cumulative incidence of relapse, CR complete remission, CRD cumulative response duration, CRh CR with partial hematologic recovery, CRi CR with incomplete hematologic recovery, CRp CR with incomplete platelet recovery,CRS cytokine release syndrome, CR1 first complete remission, DFS disease-free survival, DOR duration of response, EFS event-free survival, FA fludarabine + cytarabine, HLH/MAS hemophagocytic lymphohistiocytosis/macrophage activation syndrome, HSCT hematopoietic stem cell transplantation, ICANS immune effector cell-associated neurotoxicity syndrome, KMT2Ar KMT2A-rearranged,LFS leukemia-free survival, MRD minimal residual disease, MSD matched sibling donor, ORR overall response rate, OS overall survival, PFS progression-free survival, Ph- Philadelphia chromosome-negative, Pts Patients, R/R relapsed/refractory, RFS relapse-free survival, SOS sinusoidal obstruction syndrome, URD unrelated donor Table 2Summary of Key Clinical Studies in KMT2A-Rearranged B-cell Acute Lymphoblastic LeukemiaTherapeutic CategoryIntervention & Study DetailsPatients (n)KMT2Ar Cohort (n)OutcomesSelected Notable Adverse Events (Grade ≥ 3)conventional chemotherapy & HSCT• ECOG2993 (NCT00002514) [7]• intensive chemotherapy ± HSCT• phase 3de novo adult ALLt(4;11)-positive B-ALL (n = 85)CR1 in t(4;11) ALL: 93%5-year OS/EFS in t(4;11) ALL: 35%/34%Relapse rate in t(4;11) ALL: 45%5-year OS in CR1 HSCT(MSD/URD): 56%/67%not availableimmunotherapy• MD Anderson Cancer Center study (NCT02877303) [16]• hyper-CVAD + blinatumomab• Phase 2de novo Ph- B-ALL (n = 38)KMT2Ar B-ALL (n = 3)CR in all pts: 100%3-year OS in all pts: 81%3-year RFS in all pts: 73%3-year OS in high-risk pts: 76%3-year RFS in high-risk pts: 66%CRS (grade ≥ 3: 3%); neurological events (grade 3: 11%); no treatment‑related deaths; treatment discontinuation due to neurotoxicity (3%)• ECOG-ACRIN E1910 (NCT02003222) [17]• blinatumomab + chemotherapy vs. chemotherapy• phase 3MRD-negative Ph- B-ALL (n = 224)KMT2Ar B-ALL (n = 66)•n = 11 (blin group)•n = 8 (chemo group)3-year OS: 85% (blin + chemo) vs. 68% (chemo)3-year RFS: 80% (blin + chemo) vs. 64% (chemo)neurologic or psychiatric adverse event (grade ≥ 3): 23% (blin + chemo) vs. 5% (chemo)• GRAALL-2014-QUEST (NCT03709719) [19]• blinatumomab vs. chemotherapy (consolidation/maintenance)• phase 2high-risk Ph- B-ALLKMT2Ar B-ALL (n = 16)2.5-year OS: 79% (blin) vs. 76% (chemo)2.5-year DFS: 72% (blin) vs. 54% (chemo)2.5-year CIR: 20% (blin) vs. 41% (chemo)not available• Lu et al. (NCT05557110) [20]• reduced-dose chemotherapy + blinatumomab induction• phase 2de novo Ph- B-ALL (n = 35)KMT2Ar B-ALL (n = 3)response rate after 2–4 weeks blin in all pts: 100%1-year OS in all pts: 97.1%1-year PFS in all pts: 82.2%CRS (grade ≥ 3: 9%); ICANS (any grade: 14%; all grade 1); no deaths within 4 weeks of induction• MD Anderson Cancer Center study (NCT02877303) [31, 32]• blinatumomab and/or inotuzumab ozogamicin-based intensive immunotherapy• phase 2de novo Ph- B-ALL (n = 71)high-risk cytogenetics Ph- B-ALL (n = 31)KMT2Ar B-ALL (n = 8)CR/CRi in high-risk group: 100%3-year OS: 89% (high-risk) vs. 82% (non-high-risk)3-year RFS: 74% (high-risk) vs. 80% (non-high-risk)no SOS or secondary myeloid neoplasm• EWALL-INO (NCT03249870) [33]• inotuzumab ozogamicin + low-intensity chemotherapy• phase 2elderly (≥ 55 years) Ph- B-ALL (n = 131)KMT2Ar B-ALL (n = 11)• KMT2Ar B-ALL:1-year OS/RFS/CIR: 27.2%/22.2%/77.8%2-year OS/RFS/CIR: 9%/11.1%/88.9%SOS: 1 case (grade 3) during induction 1• MD Anderson Cancer Center study [34]• inotuzumab ozogamicin + blinatumomab (chemo-free)• phase 2elderly (≥ 70 years or 60–70 years unfit) Ph- B-ALL (n = 14)KMT2Ar B-ALL (n = 2)ORR in all pts: 93%1-year CRD/OS/PFS in all pts: 70%/73%/64%ALT elevation: 1 case (grade 3); blinatumomab-related encephalopathy: 1 case (grade 3); no SOS or secondary myeloid neoplasms• Wang et al. (NCT04684147) [39]• Inaticabtagene Autoleucel (CD19 CAR-T)• real-worldadult R/R B-ALL (n = 67)KMT2Ar B-ALL (n = 7)• KMT2Ar B-ALL:CR/CRi: 85.7%MRD-neg: 100%• total R/R B-ALL:CR/CRi: 85.4%MRD-neg: 100%median OS: not reachedmedian RFS: 12.4 monthsmedian DOR: 20.7 monthsCRS:87.5%(grade ≥ 3:12.5%); ICANS:8.3%(grade ≥ 3:6.2%); HLH/MAS:6.2%(grade ≥ 3:2.1%)menin inhibitors• AUGMENT-101 (NCT04065399) [61–64]• revumenib (SNDX-5613) monotherapy• phase 1/2R/R AL(n = 68)KMT2Ar AL(n = 46)ORR:53%CR/CRh:30%CCyR in KMT2Ar AL:64%QTc prolongation (13%)R/R KMT2Ar AL(n = 97)KMT2Ar ALL (n = 13)• KMT2Ar ALL:ORR:46%CR/CRh:23%Median DOR: not reacheddifferentiation syndrome: ALL 13% vs. AML 28% vs. MPAL 33%; febrile neutropenia (13%); nausea (13%); no TRAE-related deaths• AUGMENT-102 (NCT05326516) [65]• revumenib (SNDX-5613) + chemotherapy (FA)• phase 1R/R KMT2Ar, NPM1m, NUP98r AL (n = 27)KMT2Ar AL (n = 24)ORR: 52%CR/CRi/CRp: 52%thrombocytopenia (63%); anemia (56%); febrile neutropenia (48%)• ITCC-101/APAL2020K (NCT06376162) [66]• ziftomenib (KO-539) + chemotherapy (FA)• phase 1R/R KMT2Ar, NPM1m, NUP98r pediatric ALrecruitingnot availablenot available• NCT04811560 [67]• bleximenib (JNJ-75276617) monotherapy• phase 1R/R KMT2Ar, NPM1m AL (n = 121)KMT2Ar AL (n = 73)ORR: 47%CR/CRh/CRi: 36%neutropenia (11%); thrombocytopenia (8%); differentiation syndrome (7%)• NCT04988555 [69]• enzomenib (DSP-5336) monotherapy• phase 1/2R/R AL (HOXA9/MEIS1 driven leukemia subsets) (n = 116)KMT2Ar AL (n = 61)• KMT2Ar AL (300 mg BID + CYP3A4 inhibitor):CR/CRh: 45.5%Median OS: 11.4 monthsdifferentiation syndrome (12.9%); no grade ≥ 3 QTc prolongationAL acute leukemia, ALL acute lymphoblastic leukemia, ALT alanine aminotransferase, B-ALL B-cell ALL,CAR-T chimeric antigen receptor T-cell, CCyR complete cytogenetic response, CIR cumulative incidence of relapse, CR complete remission, CRD cumulative response duration, CRh CR with partial hematologic recovery, CRi CR with incomplete hematologic recovery, CRp CR with incomplete platelet recovery,CRS cytokine release syndrome, CR1 first complete remission, DFS disease-free survival, DOR duration of response, EFS event-free survival, FA fludarabine + cytarabine, HLH/MAS hemophagocytic lymphohistiocytosis/macrophage activation syndrome, HSCT hematopoietic stem cell transplantation, ICANS immune effector cell-associated neurotoxicity syndrome, KMT2Ar KMT2A-rearranged,LFS leukemia-free survival, MRD minimal residual disease, MSD matched sibling donor, ORR overall response rate, OS overall survival, PFS progression-free survival, Ph- Philadelphia chromosome-negative, Pts Patients, R/R relapsed/refractory, RFS relapse-free survival, SOS sinusoidal obstruction syndrome, URD unrelated donor Summary of Key Clinical Studies in KMT2A-Rearranged B-cell Acute Lymphoblastic Leukemia • ECOG2993 (NCT00002514) [7] • intensive chemotherapy ± HSCT • phase 3 CR1 in t(4;11) ALL: 93% 5-year OS/EFS in t(4;11) ALL: 35%/34% Relapse rate in t(4;11) ALL: 45% 5-year OS in CR1 HSCT(MSD/URD): 56%/67% • MD Anderson Cancer Center study (NCT02877303) [16] • hyper-CVAD + blinatumomab • Phase 2 CR in all pts: 100% 3-year OS in all pts: 81% 3-year RFS in all pts: 73% 3-year OS in high-risk pts: 76% 3-year RFS in high-risk pts: 66% • ECOG-ACRIN E1910 (NCT02003222) [17] • blinatumomab + chemotherapy vs. chemotherapy • phase 3 KMT2Ar B-ALL (n = 66) •n = 11 (blin group) •n = 8 (chemo group) 3-year OS: 85% (blin + chemo) vs. 68% (chemo) 3-year RFS: 80% (blin + chemo) vs. 64% (chemo) • GRAALL-2014-QUEST (NCT03709719) [19] • blinatumomab vs. chemotherapy (consolidation/maintenance) • phase 2 2.5-year OS: 79% (blin) vs. 76% (chemo) 2.5-year DFS: 72% (blin) vs. 54% (chemo) 2.5-year CIR: 20% (blin) vs. 41% (chemo) • Lu et al. (NCT05557110) [20] • reduced-dose chemotherapy + blinatumomab induction • phase 2 response rate after 2–4 weeks blin in all pts: 100% 1-year OS in all pts: 97.1% 1-year PFS in all pts: 82.2% • MD Anderson Cancer Center study (NCT02877303) [31, 32] • blinatumomab and/or inotuzumab ozogamicin-based intensive immunotherapy • phase 2 high-risk cytogenetics Ph- B-ALL (n = 31) KMT2Ar B-ALL (n = 8) CR/CRi in high-risk group: 100% 3-year OS: 89% (high-risk) vs. 82% (non-high-risk) 3-year RFS: 74% (high-risk) vs. 80% (non-high-risk) • EWALL-INO (NCT03249870) [33] • inotuzumab ozogamicin + low-intensity chemotherapy • phase 2 • KMT2Ar B-ALL: 1-year OS/RFS/CIR: 27.2%/22.2%/77.8% 2-year OS/RFS/CIR: 9%/11.1%/88.9% • MD Anderson Cancer Center study [34] • inotuzumab ozogamicin + blinatumomab (chemo-free) • phase 2 ORR in all pts: 93% 1-year CRD/OS/PFS in all pts: 70%/73%/64% • Wang et al. (NCT04684147) [39] • Inaticabtagene Autoleucel (CD19 CAR-T) • real-world • KMT2Ar B-ALL: CR/CRi: 85.7% MRD-neg: 100% • total R/R B-ALL: CR/CRi: 85.4% MRD-neg: 100% median OS: not reached median RFS: 12.4 months median DOR: 20.7 months • AUGMENT-101 (NCT04065399) [61–64] • revumenib (SNDX-5613) monotherapy • phase 1/2 ORR:53% CR/CRh:30% CCyR in KMT2Ar AL:64% • KMT2Ar ALL: ORR:46% CR/CRh:23% Median DOR: not reached • AUGMENT-102 (NCT05326516) [65] • revumenib (SNDX-5613) + chemotherapy (FA) • phase 1 ORR: 52% CR/CRi/CRp: 52% • ITCC-101/APAL2020K (NCT06376162) [66] • ziftomenib (KO-539) + chemotherapy (FA) • phase 1 • NCT04811560 [67] • bleximenib (JNJ-75276617) monotherapy • phase 1 ORR: 47% CR/CRh/CRi: 36% • NCT04988555 [69] • enzomenib (DSP-5336) monotherapy • phase 1/2 • KMT2Ar AL (300 mg BID + CYP3A4 inhibitor): CR/CRh: 45.5% Median OS: 11.4 months AL acute leukemia, ALL acute lymphoblastic leukemia, ALT alanine aminotransferase, B-ALL B-cell ALL,CAR-T chimeric antigen receptor T-cell, CCyR complete cytogenetic response, CIR cumulative incidence of relapse, CR complete remission, CRD cumulative response duration, CRh CR with partial hematologic recovery, CRi CR with incomplete hematologic recovery, CRp CR with incomplete platelet recovery,CRS cytokine release syndrome, CR1 first complete remission, DFS disease-free survival, DOR duration of response, EFS event-free survival, FA fludarabine + cytarabine, HLH/MAS hemophagocytic lymphohistiocytosis/macrophage activation syndrome, HSCT hematopoietic stem cell transplantation, ICANS immune effector cell-associated neurotoxicity syndrome, KMT2Ar KMT2A-rearranged,LFS leukemia-free survival, MRD minimal residual disease, MSD matched sibling donor, ORR overall response rate, OS overall survival, PFS progression-free survival, Ph- Philadelphia chromosome-negative, Pts Patients, R/R relapsed/refractory, RFS relapse-free survival, SOS sinusoidal obstruction syndrome, URD unrelated donor Conclusion and perspectives B-ALL with KMT2A rearrangements represents a rare but biologically aggressive subtype associated with high relapse rates and unfavorable long-term survival. Conventional chemotherapy, even when followed by allo-HSCT, remains insufficient for many patients. Antibody-based immunotherapies, cellular immunotherapies, and the emergence of menin inhibitors have substantially expanded the therapeutic landscape for this high-risk subtype. Nevertheless, treatment resistance driven by antigen escape, lineage switching, and acquired MEN1 mutations remains a major clinical challenge. Due to the rarity of KMT2Ar B-ALL, patient numbers in prospective clinical trials and retrospective studies are both limited, hindering definitive conclusions regarding optimal treatment strategies. There is a pressing need for multicenter, prospective trials focusing on: (1) incorporation of menin inhibitors into frontline treatment for all B-ALL patients with KMT2Ar; (2) sequential application of anti-CD19 and anti-CD22 immunotherapies during consolidation treatment to eradicate MRD and reduce the risk of antigen escape; and (3) maintenance therapy post allo-HSCT. In addition, the mechanisms and treatment strategies for myeloid lineage switch also merit investigation.